GLP-1 receptor agonists affect sexual function differently across individuals and influencing libido and hormone levels in ...

Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 vs dulaglutide among older adults. HealthDay News — For older adults with type 2 diabetes, the risk for dementia seems ...

Australia's drugs regulator has new advice on the risk of suicidal ideas and contraception issues.

Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression. A new study published in Brain and ...